Quantcast

Latest nausea Stories

2008-09-16 09:00:53

ProStrakan Group has received the FDA approval for Sancuso, which is reported to be the first and only patch to provide up to five consecutive days of control of nausea and vomiting for patients receiving a moderately or highly nausea-inducing chemotherapy regimen. According to the company, Sancuso is a transdermal system, or skin patch, that delivers granisetron, its active component and an established inhibitor of nausea and vomiting, through a thin layer of adhesive that attaches the...

2008-09-16 09:00:06

By Associated Press WASHINGTON -- Cancer patients will soon be able to use a medication patch to ease the debilitating nausea that often accompanies chemotherapy. The Food and Drug Administration said Monday it has approved the first anti-nausea patch for chemotherapy patients, intended to provide relief for up to five days. The patch, called Sancuso, is worn on the arm and delivers a widely used anti-nausea medicine, known as granisetron, through the skin. It is expected to be available...

2008-09-04 09:00:49

NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, today announced data from its Pilot Efficacy Study of its Oral Spray formulation of sumatriptan (Sumatriptan OS) compared to sumatriptan tablets, marketed as Imitrex(R)/Imigran(R), the leading triptan indicated for the treatment of migraine headaches. Migraine headaches affect over 30 million Americans and triptans account for almost $2 billion in...

2008-08-25 12:01:20

Eisai of North America and its partner Helsinn Healthcare have announced that the FDA has approved a new oral formulation of Aloxi for the prevention of chemotherapy-induced nausea and vomiting. Aloxi capsules 0.5mg for oral administration is indicated for the prevention of acute nausea and vomiting following initial and repeat courses of moderately emetogenic chemotherapy. A single 0.5mg Aloxi capsule is administered approximately one hour prior to the start of chemotherapy.

2008-08-25 09:00:26

INDIANAPOLIS, Aug. 25 /PRNewswire/ -- Data from a new study suggest that Cymbalta (duloxetine HCl) 60-120 mg once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) 24-hour average pain score, compared with placebo.(1) Results from the double-blind, 13-week, placebo-controlled study of 236 patients were presented today at the annual congress of the European Federation of Neurological Societies (EFNS) in Madrid, Spain. Duloxetine-treated...

2008-08-23 12:00:22

WOODCLIFF LAKE, N.J., Aug. 23 /PRNewswire/ -- Eisai Corporation of North America and its partner Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved a new oral formulation of ALOXI(R) (palonosetron hydrochloride) for the prevention of chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules 0.5 mg for oral administration is indicated for the prevention of acute nausea and vomiting following initial and repeat courses of moderately...

2008-07-14 18:00:12

MOUNTAIN VIEW, Calif., July 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine. MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In the company's prior Phase 2 efficacy study, MAP0004 provided pain relief in as fast as 10 minutes, with relief sustained through at least 24 hours. The study also...

2008-06-27 12:02:19

Merck & Co., Inc. today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and migraine-associated symptoms two hours after dosing compared to placebo. In addition, the efficacy results for telcagepant 300 mg were similar to the highest recommended dose of zolmitriptan,(1) an approved migraine therapy, with a lower incidence of...

2008-06-25 09:02:22

Merck & Co., Inc. announced today that the US Food and Drug Administration (FDA) has issued a complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL(R) in women ages 27 though 45. The agency issued the letter to advise that it has completed its review of the submission and that there are issues that preclude approval of the supplement within the expected review timeframe. Merck has already discussed with FDA their questions related...

2008-06-24 09:03:24

AP Pharma has completed patient enrollment in its pivotal Phase III study in chemotherapy-induced nausea and vomiting comparing the efficacy of APF530 with Aloxi for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting in both moderate and highly emetogenic chemotherapy treatments. The trial is being conducted in the US, India and Poland. Data collection will be finalized following completion of treatment of the last patients, expected near the end of July...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'